Abstract
Human T cells can be genetically modified to express tumor-associated antigens (TAA) for the induction of tumor-specific immunity, suggesting that T cells may be alternative candidates of effective antigen-presenting cells (TAPC) and may be useful in vivo as cellular cancer vaccines. The effective induction of TAA-specific T cell immune responses requires activation of T cells by CD3/CD28 antibodies and the presence of proinflammatory cytokines such as interleukin-7 (IL-7) and interleukin-12 (IL-12). Here, we describe the technique of preparing activated human TAPC pulsed with TAA peptides for the induction of tumor antigen-specific T cell immunity in vitro.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooper LJ et al (2005) Enhanced anti-lymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by co-transfer of T cells modified to present influenza MP1. Blood 105:1622–1631
Naota H et al (2006) Generation of peptide specific CD8+ T cells by phytohemagglutinin-stimulated antigen mRNA-transduced CD4+ T cells. J Immunol Methods 314:54–66
Atanackovic D et al (2003) Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods 278:57–66
Melenhorst JJ et al (2006) Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother 29:436–443
Berger C et al (2006) Analysis of transgene specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107:2294–2302
Riddell SR et al (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216–223
Fontana R et al (2008) Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 113(8):1651–1660, 19
Foster AE et al (2007) Autologous designer antigen-presenting cells by gene modification of T lymphocytes blasts with IL-7 and IL-12. J Immunother 30:506–516
Kaka AS et al (2009) Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T lymphocytes. J Immunother 32:726–736
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Foster, A.E., Song, XT. (2014). Modification of T Lymphocytes to Express Tumor Antigens. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_15
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols